BACKGROUND: In chronic nephropathies, inhibition of angiotensin-converting enzyme (ACE) is renoprotective, but can further renoprotection be achieved by reduction of blood pressure to lower than usual targets? We aimed to assess the effect of intensified versus conventional blood-pressure control on progression to end-stage renal disease. METHODS: We undertook a multicentre, randomised controlled trial of patients with non-diabetic proteinuric nephropathies receiving background treatment with theACE inhibitor ramipril (2.5-5 mg/day). We randomly assigned participants either conventional (diastolic <90 mm Hg; n=169) or intensified (systolic/diastolic <130/80 mm Hg; n=169) blood-pressure control. To achieve the intensified blood-pressure level, patients received add-on therapy with the dihydropyridine calcium-channel blocker felodipine (5-10 mg/day). The primary outcome measure was time to end-stage renal disease over 36 months' follow-up, and analysis was by intention to treat. FINDINGS: Of 338 patients who were randomised, three (two assigned intensified and one allocated conventional blood-pressure control) never took study drugs and they were excluded. Over a median follow-up of 19 months (IQR 12-35), 38/167 (23%) patients assigned to intensified blood-pressure control and 34/168 (20%) allocated conventional control progressed to end-stage renal disease (hazard ratio 1.00 [95% CI 0.61-1.64]; p=0.99). INTERPRETATION: In patients with non-diabetic proteinuric nephropathies receivingbackground ACE-inhibitor therapy, no additional benefit from further blood-pressure reduction by felodipine could be shown.
RCT Entities:
BACKGROUND: In chronic nephropathies, inhibition of angiotensin-converting enzyme (ACE) is renoprotective, but can further renoprotection be achieved by reduction of blood pressure to lower than usual targets? We aimed to assess the effect of intensified versus conventional blood-pressure control on progression to end-stage renal disease. METHODS: We undertook a multicentre, randomised controlled trial of patients with non-diabetic proteinuric nephropathies receiving background treatment with the ACE inhibitor ramipril (2.5-5 mg/day). We randomly assigned participants either conventional (diastolic <90 mm Hg; n=169) or intensified (systolic/diastolic <130/80 mm Hg; n=169) blood-pressure control. To achieve the intensified blood-pressure level, patients received add-on therapy with the dihydropyridine calcium-channel blocker felodipine (5-10 mg/day). The primary outcome measure was time to end-stage renal disease over 36 months' follow-up, and analysis was by intention to treat. FINDINGS: Of 338 patients who were randomised, three (two assigned intensified and one allocated conventional blood-pressure control) never took study drugs and they were excluded. Over a median follow-up of 19 months (IQR 12-35), 38/167 (23%) patients assigned to intensified blood-pressure control and 34/168 (20%) allocated conventional control progressed to end-stage renal disease (hazard ratio 1.00 [95% CI 0.61-1.64]; p=0.99). INTERPRETATION: In patients with non-diabetic proteinuric nephropathies receiving background ACE-inhibitor therapy, no additional benefit from further blood-pressure reduction by felodipine could be shown.
Authors: Tom Nijenhuis; Alexis J Sloan; Joost G J Hoenderop; Jan Flesche; Harry van Goor; Andreas D Kistler; Marinka Bakker; Rene J M Bindels; Rudolf A de Boer; Clemens C Möller; Inge Hamming; Gerjan Navis; Jack F M Wetzels; Jo H M Berden; Jochen Reiser; Christian Faul; Johan van der Vlag Journal: Am J Pathol Date: 2011-08-11 Impact factor: 4.307
Authors: Csaba P Kovesdy; Anthony J Bleyer; Miklos Z Molnar; Jennie Z Ma; John J Sim; William C Cushman; L Darryl Quarles; Kamyar Kalantar-Zadeh Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: N A Khan; Finlay A McAlister; Simon W Rabkin; Raj Padwal; Ross D Feldman; Norman Rc Campbell; Lawrence A Leiter; Richard Z Lewanczuk; Ernesto L Schiffrin; Michael D Hill; Malcolm Arnold; Gordon Moe; Tavis S Campbell; Carol Herbert; Alain Milot; James A Stone; Ellen Burgess; B Hemmelgarn; Charlotte Jones; Pierre Larochelle; Richard I Ogilvie; Robyn Houlden; Robert J Herman; Pavel Hamet; George Fodor; George Carruthers; Bruce Culleton; Jacques Dechamplain; George Pylypchuk; Alexander G Logan; Norm Gledhill; Robert Petrella; Sheldon Tobe; Rhian M Touyz Journal: Can J Cardiol Date: 2006-05-15 Impact factor: 5.223
Authors: Louise C Evans; Robert P Ryan; Elizabeth Broadway; Meredith M Skelton; Theresa Kurth; Allen W Cowley Journal: Hypertension Date: 2014-12-08 Impact factor: 10.190